• Age 10-21 years

• Provider diagnosis of T2D

• Stable medication regimen for 2 weeks before screening visit (No addition or removal of medications and no more than 20% change in insulin dose)

• ≥ 1 month from T2D diagnosis

• Taking regular metformin (not extended-release formula)

• Ability to wear CGM for a total of 6 weeks while in the study.

• English or Spanish speakers.

• Willing to abide by recommendations and study procedures.

• Willing and able to sign the Informed Consent Form (ICF) and/or has a parent or guardian willing and able to sign the ICF.

• Participant and parent(s)/guardian(s) willingness to participate in all training sessions as directed by study staff. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.